Legislative Hurdles Anticipated for Biopharma in 2023

As the 118th Congress kicks into gear, biopharma industry observers speculate that 2023 may be a challenging year.

Mergers and acquisitions, down in Q4, may see regulations become more stringent this session. Similarly, probes of the FDA’s accelerated approval process could bring tighter regulations.